Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease

References

• National Heart, Lung, and Blood InstituteMorbidity and Mortality: 2009 chart book on cardiovascular, lung, and blood diseasesUS Department of Health and Human Services, Public Health Services, National Institutes of Health http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf. Accessed January 2010.
   Google Scholar
• TinkelmanDCorselloPChronic obstructive pulmonary disease: the impact occurs earlier than we thinkAm J Manag Care2003976777314626474
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPMAJenkinsCRHurdSS Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary Report 2005.
   Google Scholar
• BriggsDDJrChronic obstructive pulmonary disease overview: prevalence, pathogenesis, and treatmentJ Manag Care Pharm200410S3S1015253681
   PubMed Web of Science ®Google Scholar
• TinkelmanDGPriceDBNordykeRJHalbertRJMisdiagnosis of COPD and asthma in primary care patients 40 years of age and overJ Asthma200643758016448970
   PubMed Web of Science ®Google Scholar
• BR Celli W. MacNee and committee members.Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paperEur Respir J20042393294615219010
   PubMed Web of Science ®Google Scholar
• ManninoDMCOPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneityChest2002121121S126S12010839
   PubMed Web of Science ®Google Scholar
  CohenBHBallWCJrBrashearsSRisk factors in chronic obstructive pulmonary disease (COPD)Am J Epidemiol1997105223232300564
   PubMed Web of Science ®Google Scholar
• CelliBRStandards for the optimal management of COPD: a summaryChest19981132832879498940
   PubMed Web of Science ®Google Scholar
• FergusonGTRecommendations for the management of COPDChest200011723S28S10673470
   PubMed Web of Science ®Google Scholar
• BarclayLTiotropium more effective than salmeterol in COPD. Medscape medical newsThorax20035839940412728159
   PubMed Web of Science ®Google Scholar
• FlemingTDrug Topics Red BookMontvale, NJThompson PDR2006
   Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther200123129631011558866
   PubMed Web of Science ®Google Scholar
• CleemputIKestelootKEconomic implications of non-compliance in health careLancet20023592129213012090976
   PubMed Web of Science ®Google Scholar
• HorwitzRIHorwitzSMAdherence to treatment and health outcomesArch Inter Med199315318631868
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAPMImproved health outcomes in patients with COPD during 1year’s treatment with tiotropiumEur Respir J20021920921611871363
   PubMed Web of Science ®Google Scholar
• Van NoordJABantjeTAElandMEKorduckiLCornelissenPJA randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary diseaseThorax20005528929410722768
   PubMed Web of Science ®Google Scholar
• TinkelmanDCorselloPMcClureDYinMOne-year outcomes from a disease management program for chronic obstructive pulmonary diseaseDis Manag Health Outcomes2003114959
   Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
   PubMed Web of Science ®Google Scholar
• RennardSIAndersonWZuwallackRUse of a Long-acting Inhaled β-2 Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary DiseaseAm J Crit Care200116310871092
   Web of Science ®Google Scholar
• BriggsASculpherMAn introduction to Markov modeling for economic evaluationPharmacoeconomics199313322338
   Google Scholar
• TreeAge Pro 2005Users ManualTreeAge Software, Inc.
   Google Scholar
• DonohueJFvan NoordABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD Patients treated with tiotropium or salmeterolChest2002122475512114338
   PubMed Web of Science ®Google Scholar
• KamalKMillerLKavookjjianJMadhavanSAlternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritisSemin Arthritis Rheum200636505916887468
   PubMed Web of Science ®Google Scholar
• NaimarkDKrahnMDNaglieGRedelmeierDADetskyASPrimer on Medical Decision Analysis: Part 1 – Getting StartedMed Decis Making1997171231259107606
   PubMed Web of Science ®Google Scholar
• Maximum Allowable Charges. An equal access/equal opportunity university Available at http://www.purdue.edu/HR/Benefits/mac.htm. Accessed December, 2006.
   Google Scholar
• Bradley-KennedyCScaleraACramerJATreatment persistence and compliance with medications for chronic obstructive pulmonary diseaseCan Respir J200714252917315055
   PubMed Web of Science ®Google Scholar
• HoltSMasoliMBeasleyRIncreasing compliance with inhaled corticosteroids through the use of combination therapyJ Allergy Clin Immun200411321922014767433
   PubMed Web of Science ®Google Scholar
• CochraneGMHorneRChanezPCompliance in asthmaRespir Med19999376376910603624
   PubMed Web of Science ®Google Scholar
• CantorSBCost-effectiveness analysis, extended dominance, and ethics – a quantitative assessmentMed Decis Making1994142592657934713
   PubMed Web of Science ®Google Scholar
• ManiadakisNTzanakisNFragoulakisVHatzikouMSiafakasNEvaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease in GreeceCurr Med Res Opin2006221599160716870084
   PubMed Web of Science ®Google Scholar
• FriedmanMMenjogeSSAntonSFKestenSHealthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD)Pharmacoeconomics20042274174915250751
   PubMed Web of Science ®Google Scholar
• RuizGAFernandezFLCrespoMCost-effectiveness analysis of tiotropium compared to ipratropium and salmeterolArch Bronconeumol20054242248
   Google Scholar
• OostenbrinkJBVan NoordJAVinckenWOne-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary diseaseEur Respir J20042324124914979498
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBMolkenFitzgeraldJMProbabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countriesValue Health20058324615841892
   PubMed Web of Science ®Google Scholar
• LeeKHPhuaJLimTKEvaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in SingaporeRespir Med20061002190219616635566
   PubMed Web of Science ®Google Scholar
• WatkinsJBMinshallMESullivanSDApplication of economic analyses in US managed care formulary decisions: a private payer’s experienceJ Manag Care Pharm20061272673517249905
   PubMed Web of Science ®Google Scholar
• JonesPCalverleyPMCelliBThe towards a revolution in COPD health (torch) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 yearsChest2006130177s
   Web of Science ®Google Scholar
• TashkinDPBartolome CelliMDSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet200336144945612583942
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20021661084109112379552
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med200714654555517310045
   PubMed Web of Science ®Google Scholar
• NajafzadehMarraSadatsafaviAaronCost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPDThorax20086362967
   Web of Science ®Google Scholar